Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

<p>NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/galectin-therapeutics-to-present-update-on-its-belapectin-liver-cirrhosis-program-at-the-20th-edition-of-discovery-on-target-meeting-in-boston-september-25-28-2023/">Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>